Ceftazidime/avibactam combined with colistimethate sodium successfully cures carbapenem-resistant Pseudomonas aeruginosa-induced brain abscess in a child post-craniotomy: a case report
- PMID: 39364315
- PMCID: PMC11446902
- DOI: 10.3389/fonc.2024.1444172
Ceftazidime/avibactam combined with colistimethate sodium successfully cures carbapenem-resistant Pseudomonas aeruginosa-induced brain abscess in a child post-craniotomy: a case report
Abstract
The treatment of brain abscess induced by carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a clinical challenge around the world. Apart from novel β-lactam/β-lactamase inhibitors and polymyxins, there are few sufficiently powerful antibiotics that are effective against CRPA-induced infections. Considering the blood-brain barrier factor, there are even fewer drugs that can be used to treat intracranial CRPA-induced infections. In this article, we reported a case of CRPA-induced brain abscess that was successfully treated with intravenous ceftazidime/avibactam and intrathecal colistimethate sodium in a child after intracranial tumor resection.
Keywords: brain abscess; carbapenem-resistant pseudomonas aeruginosa; ceftazidime/avibactam; central nervous system infections; colistimethate sodium.
Copyright © 2024 Yuan, Zong, Ren, Zong and Li.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures





Similar articles
-
In Vitro Activity of New β-Lactam-β-Lactamase Inhibitor Combinations and Comparators against Clinical Isolates of Gram-Negative Bacilli: Results from the China Antimicrobial Surveillance Network (CHINET) in 2019.Microbiol Spectr. 2022 Aug 31;10(4):e0185422. doi: 10.1128/spectrum.01854-22. Epub 2022 Jul 12. Microbiol Spectr. 2022. PMID: 35862963 Free PMC article.
-
Successful treatment of ventriculitis caused by Pseudomonas aeruginosa and carbapenem-resistant Klebsiella pneumoniae with i.v. ceftazidime-avibactam and intrathecal amikacin.Am J Health Syst Pharm. 2018 Jul 1;75(13):953-957. doi: 10.2146/ajhp170632. Am J Health Syst Pharm. 2018. PMID: 29941534
-
Prevalence and molecular characteristics of ceftazidime-avibactam resistance among carbapenem-resistant Pseudomonas aeruginosa clinical isolates.J Glob Antimicrob Resist. 2024 Mar;36:276-283. doi: 10.1016/j.jgar.2024.01.014. Epub 2024 Feb 1. J Glob Antimicrob Resist. 2024. PMID: 38295902
-
Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.Infection. 2022 Dec;50(6):1409-1423. doi: 10.1007/s15010-022-01876-x. Epub 2022 Jul 4. Infection. 2022. PMID: 35781869 Review.
-
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.Clin Infect Dis. 2016 Jul 15;63(2):234-41. doi: 10.1093/cid/ciw243. Epub 2016 Apr 20. Clin Infect Dis. 2016. PMID: 27098166 Free PMC article. Review.
References
-
- Tamma PD, Aitken SL, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. (2022) 75:187–212. doi: 10.1093/cid/ciac268 - DOI - PMC - PubMed
-
- Dey R, Bishayi B. Ciprofloxacin and dexamethasone in combination attenuate S. aureus induced brain abscess via neuroendocrine-immune interaction of TLR-2 and glucocorticoid receptor leading to behavioral improvement. Int Immunopharmacol. (2021) 97:107695. doi: 10.1016/j.intimp.2021.107695 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources